De-risk the development of novel therapies. Fueled by AI.
Based on a unique wealth of proprietary and expertly curated data, Intelligencia has been pioneering the use of Machine Learning algorithms to assess, quantify, and reduce the risk of clinical development.
Software that delivers sustained, positive impact.
Our solutions enable you to minimize risks in drug development, streamline productivity and lower cost across key aspects of pre-clinical and clinical development, Portfolio Strategy, and Business Development.
Newsroom
Learn more about Intelligencia through our latest press clippings and more!
Intelligencia AI Appoints Névine Zariffa as Scientific Advisory Board Chair
Strategies to de-risk development of immune checkpoint inhibitor combinations
Machine learning approaches to predict drug efficacy and toxicity in oncology
Mispriced risk: Finding undervalued biopharma business development opportunities
AI can deliver better healthcare and longevity for all. Here's how.
Intelligencia Raises $12M to Reduce the Risk of Clinical Research, Improve R&D Productivity, and Accel erate Scientific Breakthroughs
Intelligencia.ai: Machine learning: A Catalyst for Drug Development
Take the risk out of clinical drug development
Optimizing Real World Data for Therapeutic Development: The Role of Artificial Intelligence
Dimitrios Skaltsas: AI at the heart of drug-development company
What our users are saying
